The Limits Of REMS: Opioid Debate Shows Shortcomings Of New FDA Powers

An FDA advisory committee's discussion of an agency proposal to manage the risk of long-acting/extended release opioids underscores the limits of the agency's authority to curb misuse of prescription medications even with the new safety powers enshrined in the 2007 renewal of the user fee legislation